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Abstract
 
Current treatments for autoantibody-mediated diseases, such as lupus, can cause nonspecific
immune suppression. In this paper, we used a bioinformatic approach to identify major histo-
compatibility complex class I–binding epitopes in the heavy chain variable region of anti-DNA
antibodies from lupus-prone (NZB/NZW F1) mice. Vaccination of such mice with plasmid DNA
 
vectors encoding these epitopes induced CD8
 
 
 
 T cells that killed anti-DNA antibody-producing B
cells, reduced serum anti-DNA antibody levels, retarded the development of nephritis, and
 
improved survival. Vaccine-mediated induction of anti-V
 
H
 
 cytotoxic T lymphocytes that ablate
autoreactive B cells represents a novel approach to treat autoantibody-mediated diseases.
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Introduction
 
B cells are essential for the development of systemic autoim-
mune disease such as lupus. Genetic deletion of B cells
 
protects mice from developing lupus (1). Drugs such as cy-
clophosphamide that are currently used to treat lupus deplete
B cells (2); the treatment is effective but causes nonspecific
immune suppression. As organ damage in lupus is caused, at
least in part, by autoantibodies such as anti-dsDNA Ab (3,
4), depletion of dsDNA-specific B cells might inhibit lupus
without causing nonspecific immune suppression.
 
The (NZB 
 
 
 
 NZW) F1 (BWF1)
 
*
 
 mouse is a model of
autoantibody-mediated disease that shares many features
with human lupus (5). Although these mice carry a diverse
autoreactive B cell repertoire, there is a limited clonality for
anti-DNA B cells (4, 6–8). In fact, some heavy chain variable
 
region (V
 
H
 
) genes are markedly increased in Ig from BWF1
mice, but are rarely used in Ig of normal mice (7, 8).
Additionally, V
 
H
 
 regions of Ig molecule contain sequences
that can bind MHC class II molecules (9); such sequences
are frequently shared among autoantibodies (10, 11). For
example, all anti-chromatin autoantibody clones tested
express a shared replacement mutation in their framework
region, which creates an MHC class II–binding motif in all
clones (10). Similarly, MHC class II–binding epitopes
 
frequently occur in anti-DNA and other lupus-related au-
toantibodies, but are uncommon in the normal Ig repertoire
(11). Thus, it may be possible to target autoantibody-
producing B cells while sparing normal immune defenses.
Ig molecules contain epitopes that can function as targets
for T cell–mediated immune responses (9–13). B cells can
 
process and present such epitopes from the V
 
H
 
 of their own
Ig (14–16) and activate CD4
 
 
 
 and CD8
 
 
 
 T cells (9–16).
Here, we hypothesize that CD8
 
 
 
 CTLs that are specific for
an Ig V
 
H
 
 epitope will recognize and lyse B cells that can
process and display the relevant V
 
H
 
 epitope on their surface
MHC class I molecules. To test this idea, we identified
MHC class I–binding epitopes in the V
 
H
 
 of BWF1-derived
anti-DNA mAbs. Vaccination of BWF1 mice with plasmid
DNA vectors that encode such epitopes activated CTL
response against anti-DNA Ab-producing B cells, inhibited
anti-DNA Ab production and lupus nephritis, and pro-
longed survival.
 
Materials and Methods
 
Mice.
 
BWF1 and (BALB/c 
 
 
 
 NZW) F1 (CWF1) mice
were obtained from the The Jackson Laboratory or bred locally.
Female mice were used in all experiments.
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Peptides.
 
8- to 15-mer peptides (see Fig. 1 C) were synthe-
sized using F-moc chemistry, purified to a single peak, and tested
for mol wt by mass spectrometry (Sigma-Aldrich).
 
B Cell Hybridomas.
 
B cell hybridomas, including dsDNA-
specific (A6.1 and BWds3) and non-DNA binding (375–57 and
375–100), were established from BWF1 mice by fusion of their
spleen cells with a nonsecreting murine myeloma cell line (4, 17).
 
MHC Binding Assay.
 
Transporter associated with antigen
processing (TAP)-deficient T2.K
 
d
 
, T2.L
 
d
 
, or T2.D
 
d
 
 cells were
pulsed with peptides at 26
 
 
 
C overnight, washed, and stained with
conjugated Abs against relevant MHC class I molecules (18, 19).
MHC class I expression was analyzed by flow cytometry. The
fluorescence index was calculated by the mean fluorescent inten-
sity (MFI) of MHC class I on T2 cells, using the following for-
mula (13): fluorescence index 
 
 
 
 MFI (T2 cells pulsed with pep-
tide)/MFI (T2 cells not pulsed with the peptide) 
 
 
 
 1.
 
Construction of Plasmid DNA Vectors.
 
First, we substituted the
human CMV promoter in a mammalian expression vector, pCI
(Promega) with the murine CMV promoter that was excised
from a plasmid pDK6 (20). The resultant plasmid, termed pCD,
was used to construct two minigenes, namely pCD.VH1, that en-
codes a single peptide (VH1), and pCD.III that encodes three
peptides, VH1 plus VH2 plus VH3 (Fig. 1 C). The individual
peptide units in the multi-epitope minigene, pCD.III, were sepa-
rated by glycine (Gly)-Gly linkers, as proteasomal cleavage of cel-
lular proteins generally occurs after the second Gly (21).
To construct pCD.III, four oligonucleotides (oligo), each 
 
 
 
60
nucleotides with a 20-mer overlapping complementary sequence
(underlined), were synthesized at the University of Cincinnati
DNA Core as follows: Oligo 1: 5
 
 
 
-CAGAGAATTCGC-
CGCCGCCATGGGCTACTTTATGAACTGGGTGAAGC-
AGAGCCA-3
 
 
 
; Oligo 2: 5
 
 
 
-CCCTTGAACTTCTGGTTG-
TAGAAACCACCAAGGCTCTTTCCATGGCTCTGCTTCA-
CCCAGTTC-3
 
 
 
; Oligo 3: 5
 
 
 
-TACAACCAGAAGTTCAAGG-
GCAAGGCCACATTGGGTGGTTCTGAGGACTCTGCACT-
CTA-3
 
 
 
; and Oligo 4: 5
 
 
 
-ACGCGGATCCTTAATCTCT-
TGCACAATAATAGAGTGCAGAGTCCTCAGA-3
 
 
 
. The final
minigenes were assembled by extending the overlapping oligos
using PCR reaction under the following conditions: 94
 
 
 
C for 15 s,
55
 
 
 
C for 30 s, 72
 
 
 
C for 50 s, for a total of 35 cycles, then 72
 
 
 
C
extension for 5 min. The PCR product was purified using a QIA-
EXII gel extraction Kit (QIAGEN), and digested with EcoRI
and BamHI, gel purified, and cloned in frame downstream to a
Kozak sequence (22) and an initiation codon into the multiclon-
ing site of the pCD. The single epitope minigene, pCD.VH1,
was constructed using a similar approach. For large-scale
preparations, plasmid DNA was purified from transformed 
 
Esche-
richia coli
 
, JM109, and concentrated using endo-free columns
(QIAGEN). The concentrates were analyzed at A260 and A280
and by agarose gel electrophoresis and ethidium bromide stain-
ing, and suspended in endo-free PBS (Sigma-Aldrich) for in vivo
injections.
 
Isolation of T and B Cells.
 
Spleen cells were enriched for T
and B cells using a VarioMACS system and microbead-coated
Abs against mouse CD90 (Thy1.2) and CD45R (B220), respec-
tively (Miltenyi Biotech). The purity of isolated populations
ranged from 92–98%.
 
CTL Assay.
 
CTL activity was tested by the lactate dehydrog-
enase (LDH) release assay using a CytoTox 96
 
®
 
 nonradioactive
cytotoxicity assay kit (Promega). Briefly, target cells (1–3 
 
  
 
10
 
4
 
 B
cells) were cocultured with effector cells (T cells from vaccinated
or control mice) at various ratios for 6–8 h in serum-free AIMV
medium (GIBCO BRL). Spontaneous LDH release from the ef-
 
fector and target cells was controlled by separate incubation of
the respective cell populations. The percent cytotoxicity was cal-
culated using the formula: % cytotoxicity 
 
 
 
 ([E
 
 
 
Se
 
 
 
St]) /
([Mt
 
 
 
St]) 
 
 
 
 100, where E stands for the experimental LDH re-
lease in effector plus target cell cocultures; Se, the spontaneous
release by effector cells alone; St, the spontaneous release by tar-
get cells alone; and Mt, the maximal release by target cells.
 
ELISA for the Detection of Anti-DNA and Antipeptide Abs, Total
IgG, and Cytokines.
 
For detection of anti-DNA Ab (4, 9), ni-
trocellulose-filtered, sonicated calf thymus DNA (Sigma-Aldrich)
was coated onto the high-binding EIA/RIA plates (Costar). After
blocking, samples were added, followed by alkaline phosphatase-
conjugated anti–mouse IgG. Substrate para-nitrophenyl phos-
phate (Sigma-Aldrich) was then added; plates were read at 405
nm using a Labsystems Multiskan ELISA reader. Anti-DNA Ab
levels are expressed as U/ml, which was calculated using a posi-
tive standard serum. Antipeptide Abs were detected using a simi-
lar protocol, as described previously (23). Sandwich ELISA using
Ab pairs and recombinant cytokines (BD Biosciences) or mouse
IgG (Southern Biotechnology Associates, Inc.) determined the
quantities of IFN-
 
 
 
, TGF-
 
 
 
, IL-4, IL-13, and IgG (9, 23).
 
Assessment of Lupus.
 
Proteinuria was estimated using Albustix
(Ames). Severe proteinuria was defined as 
 
 
 
300 mg/dl (3
 
 
 
) on
two consecutive examinations (9). Kidneys were fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned to stain
with periodic acid Schiff (PAS) and hematoxylin and eosin
(H&E). Stained sections were scored for histological changes in a
blinded fashion.
 
Statistical Analysis.
 
Significance of difference was examined
using Student’s 
 
t
 
 test for anti-DNA Ab and cytokines. A log-rank
test was performed to compare the proportion of surviving mice
and mice with severe proteinuria.
 
Results
 
Applying Bioinformatics to Identify the V
 
H
 
-derived CTL
Epitopes.
 
The V
 
H
 
 sequence of an anti-dsDNA mAb,
A6.1, that was derived from a nephritic BWF1 mouse (4)
was screened for the presence of epitopes: (a) that would
strongly activate CTLs; and (b) that can be efficiently pro-
cessed to bind MHC class I molecules in target B cells (24–
26). To select the epitopes that can be efficiently processed,
we determined the proteasomal cleavage probability using
an MHC class I antigenic peptide processing prediction
program (MAPPP; reference 26). The calculated cleavage
probability and MHC binding scores were combined to
determine an overall score (26). In the V
 
H
 
 of an anti-DNA
mAb, A6.1, four epitopes were predicted to strongly bind
BWF1 MHC class I molecule, K
 
d
 
, and one epitope was
predicted to bind L
 
d
 
 (Fig. 1 A).
These predictions were confirmed in a cellular binding
assay where we incubated peptides shown in Fig. 1 A with
T2.K
 
d
 
, T2.L
 
d
 
, or T2.D
 
d
 
 cell lines, which are T2 cells trans-
fected with MHC class I molecules, H2-K
 
d
 
, L
 
d
 
, or D
 
d
 
, re-
spectively (Fig. 1 B). MHC class I expression was analyzed
by flow cytometry, and the fluorescence index was calcu-
lated, as described in Materials and Methods. As T2 cells
are deficient in TAP molecules, exposure to exogenous
peptides will increase MHC class I expression on T2 cells
that are transfected with the relevant MHC class I molecule 
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(18, 19). For example, the second epitope, KFKGKATL,
induced a high K
 
d
 
 expression when incubated with T2.K
 
d
 
cells (fluorescence index 
 
 
 
 1.04), but caused no increase in
K
 
d
 
 expression upon incubation with T2.L
 
d
 
 (fluorescence
index 
 
 
 
 0.02). Similar experiments were performed to
confirm the MHC class I binding of other V
 
H
 
 epitopes.
 
Selection of V
 
H
 
 Peptides to Induce CTL Response in BWF1
Mice.
 
As CD8
 
 
 
 CTL priming is generally more efficient in
the presence of CD4
 
 
 
 T cell help (27), we selected peptides
that could activate both CD4
 
 
 
 and CD8
 
 
 
 T cells. Three
such peptides, denoted as VH1, VH2, and VH3 were identi-
fied in the V
 
H
 
 of A6.1 (Fig. 1 C). The peptide VH1 binds a
MHC class II molecule, I-E
 
d
 
 (9), and contains a 9-mer K
 
d
 
-
binding epitope that has high cleavage probability and over-
all scores (Fig. 1 A). Peptide VH2 binds MHC class II mole-
cules, I-E
 
d
 
 and I-E
 
z
 
 (9), and contains an 8-mer K
 
d
 
-binding
epitope that has moderate cleavage probability and overall
scores. Peptide VH3 binds MHC class II, I-A
 
z
 
 (9), and is
predicted to bind MHC class I of the H-2
 
z
 
 haplotype based
on its ability to activate CD8
 
 
 
 T cells in NZW parents of
BWF1 mice. As MHC class I prediction and binding assays
are not available for the H-2
 
z
 
 haplotype, we immunized
NZW mice that carry H-2
 
z
 
 haplotype with the A6.1 heavy
chain and determined recall in vitro proliferation of their
splenic CD8
 
 
 
 T cells to overlapping peptides from the V
 
H
 
 of
A6.1 (unpublished data). An 8-mer epitope (underlined se-
quence in the VH3 peptide, Fig. 1 C) activated strong CD8
 
 
 
T cell proliferation in NZW mice.
Upon immunization with the synthetic VH1 peptide in
CFA, normal CWF1 mice exhibited strong CD8
 
 
 
 T cell
proliferative responses; lupus-prone BWF1 mice, on the
other hand, had a weak or no response (unpublished data).
As antigens administered as genes via plasmid DNA or viral
vectors generally activate strong CD8
 
 
 
 T cell responses
(28, 29), this mode of peptide delivery might overcome the
impairment in CD8
 
 
 
 CTL response in lupus mice. There-
fore, we assembled the cDNA encoding a single peptide,
VH1, or multiple peptides, VH1 plus VH2 plus VH3, by
PCR and cloned them into a modified plasmid DNA vec-
tor (pCD) to construct two minigenes, pCD.VH1 and
pCD.III, respectively (see Materials and Methods). The
presence of gene inserts in the pCD.VH1 and pCD.III was
verified by sequencing from the downstream of mCMV
promoter using a mCMV primer (5
 
 
 
-CGACCAGCGTC-
GGTACCGTCGCAG-3
 
 
 
).
 
Plasmid DNA Vectors that Encode V
 
H
 
 Peptides Induce Pep-
tide-specific CTL and Ab Responses.
 
We first determined if
the pCD.VH1 or pCD.III induce peptide-specific re-
Figure 1. Identification and selection of VH peptides to induce CTL response in BWF1 mice. (A) Prediction of MHC class I–binding epitopes in the
VH of an anti-DNA mAb, A6.1. The cleavage probability, MHC–peptide binding, and overall scores were assigned by computer prediction software
(reference 26). The overall score combines the calculated cleavage probability and the binding score (reference 26). (B) Confirmation of predicted
epitopes in a cellular binding assay. Kd expression was analyzed in T2.Ld (Control) or T2.Kd cells that were stained with an anti-Kd mAb after
overnight incubation without (No peptide) or with peptide VH2 (Peptide KL). Results are from one of three similar experiments. (C) Selection
of peptides that have both MHC class I– and class II–binding motifs in the VH of an anti-DNA mAb, A6.1. The MHC class I–binding epitopes are
underlined (thick lines); thin lines over the VH sequence denote MHC class II-binding epitopes. Mapping of MHC class II–binding epitopes is described
elsewhere (reference 9).734 Anti-VH Cytotoxic T Lymphocytes Ablate Autoreactive B Cells in Lupus
sponses in vivo. Inclusion of MHC class II–binding
epitopes in the minigene constructs allowed us to test pep-
tide-specific Ab responses. BWF1 mice were inoculated
with 50  g each of three intradermal injections of peptide
expression vectors (pCD.VH1 or pCD.III) at weekly inter-
vals. Control mice received the same amount of a null vec-
tor, pCD, or the same volume of PBS. Sera collected 10 d
after the last injection were tested for anti-VH1, anti-VH2,
and anti-VH3 Abs (Fig. 2 A). Inoculation of mice with
pCD.VH1 increased anti-VH1 but not anti-VH2 or anti-
VH3 Abs, and inoculation with pCD.III induced Abs that
reacted with all three peptides, VH1, VH2, or VH3.
To determine the induction of peptide-specific CTLs,
spleen cells from the vaccinated and control mice were cul-
tured with 10  g/ml each of the relevant or irrelevant pep-
tides and 100 U/ml hIL-2 for 5 d. Purified T cells from these
cultures were tested for CTL activity against B cells from
MHC-matched (H-2du), normal CWF1 mice (Fig. 2 B). T
cells from the pCD.III-vaccinated mice did not exhibit CTL
activity against CWF1 B cells (Fig. 2 B, left panel), unless they
were pulsed with the VH peptides (Fig. 2 B, middle panel).
The CTL activity was abolished when CD8  T cells were de-
pleted by an anti-CD8 mAb (0.5  g/106 cells of clone 53–6.7;
BD Biosciences; Fig. 2 B, right panel). T cells from the
pCD.VH1-vaccinated mice exhibited CTL activity against
CWF1 B cells when pulsed with the VH1 (Fig. 2 B, middle
panel), but not when pulsed with an irrelevant (VH3) peptide
(unpublished data). Similar results were obtained using target
B cells from young male BWF1 mice (unpublished data).
Thus, VH peptide-specific CD8  CTLs recognize and lyse B
cells that display the relevant VH epitope.
VH Peptide Expression Vectors Activate CD8  T Cells that
Kill Anti-DNA B Cell Hybridomas. To test if the mini-
gene-induced anti-VH CTLs recognize and lyse B cells that
may express naturally processed VH epitopes, BWF1 mice
were inoculated with three intradermal injections of PBS,
pCD, or pCD.III at weekly intervals. 10 d after the last in-
jection, splenic T cells from these mice were tested for CTL
activity against two BWF1-derived B cell hybridomas: A6.1,
a dsDNA-specific hybridoma (4) that expresses Ig that con-
tains the VH1/VH2/VH3 sequences, and 375–57, a nonau-
toreactive hybridoma (17) that expresses Ig that does not
contain these sequences (Fig. 3 A). Results show that T cells
from pCD.III-vaccinated mice exhibited CTL activity
against A6.1, but not against 375–57. Depletion of CD8  T
cells by the addition of anti-CD8a mAb to the cultures abro-
gated the CTL activity (unpublished data). Similar results
were obtained using another set of dsDNA-specific and non-
autoreactive B cell hybridomas. Thus, anti-VH CTLs can kill
B cells that express Ig that contains the VH epitopes, but do
not kill B cells that do not express the relevant VH epitopes.
VH Minigene-induced CTLs Kill B Cells from Diseased
BWF1 Mice. To determine if minigene-induced, VH
peptide-specific CD8  T cells kill autoreactive B cells from
lupus mice, T cells from pCD.III-vaccinated or control
mice were tested for CTL activity against B cells from un-
treated BWF1 mice (Fig. 3 B). Results show that T cells
from pCD.III-vaccinated BWF1 mice induced CTL activ-
ity against B cells from 6–9-mo-old BWF1 mice that had
high levels of anti-DNA Abs, but not against B cells from
1–2-mo-old BWF1 that did not have detectable IgG anti-
DNA Ab-secreting B cells.
Figure 2. VH peptide expression vectors induce pep-
tide-specific Ab and CTL responses in BWF1 mice.
3-mo-old BWF1 mice were inoculated with three intra-
dermal injections of PBS ( ), a null (pCD,  ) or pep-
tide expression vectors (pCD.VH1,  ; pCD.III,  ) at
weekly intervals (n   9 mice per group). 10 d after the
last injection, mice were bled for detection of serum
anti-peptide Abs (A) and killed to harvest spleen cells
for CTL assays (B). (A) Serum IgG anti-VH1, anti-
VH2, and anti-VH3 Abs are expressed as the mean  
SD OD. (B) Splenic T cells pooled from five mice in
each group served as effector cells in CTL assays that
used CWF1 B cells as target cells. Minigene-induced
anti-VH T cells exhibited CTL activity against peptide-
pulsed CWF1 B cells (middle panel), but had little or
no CTL activity against unpulsed CWF1 B cells (left
panel). Depletion of CD8  T cells by the addition of
an anti-CD8a mAb to the cultures abrogated CTL
activity (right panel). Results are from one of three
similar experiments.735 Fan et al.
T Cells from VH Minigene-vaccinated Mice Inhibit IgG Anti-
DNA Ab Production In Vitro. To determine if minigene-
induced anti-VH CD8  T cells inhibit anti-DNA Ab produc-
tion, T cells from pCD.III-vaccinated mice were cocultured
with B cells from untreated, 9-mo-old, nephritic BWF1
mice; 5th d culture supernatants were tested for anti-DNA
Abs. As shown in Fig. 4 A, IgG anti-DNA Ab production
was significantly decreased in the presence of T cells from
pCD.III-vaccinated mice compared with pCD- or PBS-
injected controls. This decrease in anti-DNA Ab production
was abrogated by the depletion of CD8  (Fig. 4 A), but
not of CD4  (unpublished data) T cells, suggesting a role
of anti-VH CD8  T cells in the inhibition of anti-DNA Ab
production.
Vaccination with VH Minigenes Reduces IgG Anti-DNA Ab
Production In Vivo. To determine if the VH minigene vac-
cination inhibits anti-DNA Ab production in vivo, we
vaccinated BWF1 mice with pCD.III, pCD, or PBS three
times at weekly intervals, and monitored serum IgG anti-
dsDNA Ab and total IgG levels (Fig. 4 B). 10 d after the
last inoculation, serum IgG anti-DNA Ab levels increased
in mice injected with the null vector (pCD) compared
with pCD.III-vaccinated mice (P   0.04), which is consis-
tent with previous reports that showed a transient increase
in anti-DNA Ab production after plasmid or bacterial
DNA immunizations (30, 31). Subsequent challenge with
peptides VH1, VH2, and VH3 at 4-mo of age accelerated
anti-DNA Ab production in the control pCD- or PBS-
injected mice, but not in the pCD.III-vaccinated mice,
which continued to have significantly lower levels of serum
anti-DNA Abs at 5 and 6 mo of age (P   0.01). Total se-
rum IgG levels, however, were not significantly decreased
in the pCD.III-vaccinated mice (Fig. 4 B, right panel).
To further examine if the decrease in anti-DNA Ab pro-
duction in pCD.III-vaccinated mice is mediated by pep-
tide-specific CTLs, we performed adoptive transfer ex-
periments wherein T cells from vaccinated mice were
transferred into naive BWF1 mice and anti-DNA Ab-pro-
ducing B cells were enumerated in spleens of recipients
(Fig. 4 C). In brief, BWF1 mice were inoculated thrice
with pCD.III or pCD. A week after the third inoculation
spleen cells from these mice were expanded in vitro with
the relevant MHC class I–binding peptides and IL-2. After
one or two cycles of stimulation, purified live T cells were
injected into 22-wk-old BWF1 mice that had moderate to
high levels of serum IgG anti-DNA Abs. 5 d after the trans-
fer, recipient animals were killed and their spleen cells were
tested for IgG anti-DNA Ab producing cells in an
ELISPOT assay, as described previously (11). Results show
that animals transferred with 5   106 T cells from pCD.III-
vaccinated mice had significantly decreased numbers of IgG
anti-DNA Ab forming cells compared with animals that re-
ceived smaller numbers (5   103) of T cells from the same
mice (P   0.04) or as compared with animals that received
the same numbers of T cells from control pCD-injected
mice (P   0.02; Fig. 4 C).
VH Minigene Vaccination Suppresses Lupus Nephritis and Im-
proves Survival. To determine the effect of vaccination
with VH minigenes on the development of lupus, BWF1
mice were vaccinated as described above and monitored for
proteinuria and survival (Fig. 5, A and B). The develop-
ment of severe proteinuria was delayed and survival was
prolonged in the pCD.III-vaccinated mice as compared
with control mice (P   0.01 to   0.001, log rank test).
Kidney sections from the vaccinated and control BWF1
mice were stained with PAS and H&E (Fig. 5 C), and exam-
ined for the active (glomerular proliferation, necrosis, cres-
cent formation, and interstitial inflammation) and chronic le-
sions (glomerulosclerosis, interstitial fibrosis, and tubular
atrophy) of lupus nephritis. Findings were similar in the two
control groups of mice (PBS- and pCD-injected), all of
which had severe glomerular proliferation and/or sclerosis in
 60% glomeruli per kidney, extensive interstitial infiltrates,
fibrous and cellular crescents, and tubular atrophy. The
pCD.III-vaccinated mice, on the other hand, had early
changes of lupus nephritis, including mesangial or diffuse
glomerular proliferation in  30% glomeruli per kidney and
interstitial infiltrates in  3 small foci per kidney. Remark-
ably, the pCD.III-vaccinated mice had minimal or no
chronic changes (glomerulosclerosis, fibrosis, and tubular at-
Figure 3. VH minigene vaccination of BWF1 mice induces anti-VH
CD8  CTLs that kill BWF1-derived primary or hybridoma B cells. 3-mo-
old female BWF1 mice were inoculated with PBS ( ), pCD ( ), or
pCD.III ( ), as described in the legend of Fig. 2. Splenic T cells pooled
from five mice in each group served as effector cells in CTL assays that
used BWF1-derived B cell hybridomas, 375–57 and A6.1 (A) or purified
splenic B cells from BWF1 mice (B) as target cells. Anti-VH T cells exhibited
CTL activity against a dsDNA-specific B cell hybridoma (A6.1) or B cells
from aged syngeneic mice (6–9-mo-old BWF1, n   4) that had high levels
of IgG anti-DNA Abs (right panels), but had little or no CTL activity
against a nonautoreactive hybridoma (375–57) or B cells from young (2-
mo-old) BWF1 mice that did not have detectable anti-DNA Ab-secreting
B cells (left panels). Results are from one of four similar experiments.736 Anti-VH Cytotoxic T Lymphocytes Ablate Autoreactive B Cells in Lupus
rophy). Thus, vaccination with pCD.III markedly retarded
the development and progression of lupus nephritis.
Peptide-specific Cytokine Responses in Spleen Cells from the
Minigene-vaccinated Mice: Enhanced TGF-  and IFN- , but
Reduced IL-4 and IL-13, Production.  Cytokines produced
during an immune response can influence the generation of
CTLs (32–34). To determine if the VH minigene vaccina-
tion alters peptide-specific cytokine production in BWF1
mice, we cultured spleen cells from the vaccinated and
control mice with or without VH peptides and measured
cytokines in supernatants (Fig. 6). TGF-  and IFN-  levels
were significantly increased, whereas IL-4 and IL-13 were
decreased in the pCD.III-vaccinated compared with pCD-
or PBS-injected mice. Such cytokine profile may contrib-
ute to the induction of potent CD8  CTL responses by
minigene vaccination (32–34).
Discussion
In this paper, we show evidence for a novel mechanism
of limiting autoantibody production: anti-DNA VH pep-
tide-reactive CD8  CTLs ablate anti-DNA autoantibody-
producing B cells. Vaccination of BWF1 mice with a mini-
gene encoding three VH-derived epitopes inhibits serum
autoantibody levels and markedly improves lupus nephritis
and survival, suggesting that these anti-VH CTLs may have
targeted a broad repertoire of autoreactive B cells.
A major question is how a few CTL epitopes from a sin-
gle VH inhibit a systemic disease that is apparently caused
by autoantibodies of diverse origin. A review of published
data on Ig VH gene usage suggests that while there are no
autoantibody-specific VH genes, certain VH genes that are
rare in Igs of normal mice are commonly used in anti-
DNA Ab (7, 8). Moreover, we and others have shown that
autoantibody VH framework regions contain T cell
epitopes (10, 11) that are commonly present in anti-DNA
and other lupus-related autoantibodies, but are uncommon
in the normal Ig repertoire (11). Thus, activation of T cells
reactive with such shared epitopes might target a broad ar-
ray of related autoreactive B cells while sparing the unre-
lated normal B cell repertoire. It is not clear how such spe-
cific T cell epitopes are created in the autoantibody VH
regions. In a recent paper, a framework (FR1) replacement
mutation that was shared among all anti-chromatin autoan-
tibody clones did not enhance chromatin binding, but cre-
ated a T cell epitope (10). These mutations may not be fre-
quent in nonautoreactive Ab. Indeed, lupus B cells exhibit
subtle alterations in the pattern of somatic mutations when
Figure 4. Minigene-induced T cells inhibit IgG anti-DNA Ab produc-
tion in vitro and in vivo. 3-mo-old BWF1 mice were vaccinated with three
weekly intradermal injections (three short arrows in panel B) of pCD.III
( ), pCD ( ), or PBS ( ) (n   15 per group). (A) Six mice in each group
were killed 10 d after the last injection, and their splenic T cells were cocul-
tured with B cells from 9-mo-old untreated BWF1 mice for 5 d in the ab-
sence or presence of three peptides. IgG anti-DNA Abs in culture superna-
tants are shown as mean   SD U/ml. *P   0.05, pCD.III versus control
(pCD or PBS) groups (Student’s t test). (B) The remaining nine mice were
challenged once subcutaneously (a long arrow) with 25  g each of peptide
VH1, VH2, and VH3 together in a 1:1 emulsion with CFA 2 wk after the
last injection. Their monthly sera were tested for anti-dsDNA Abs (left
panel) or total IgG (right panel). Results are expressed as the mean   SD.
*P    0.01 to 0.003, pCD.III versus both control groups; **P    0.04,
pCD.III versus pCD group (Student’s t test). Results are from one of two
similar experiments. (C) 10-wk-old BWF1 mice were inoculated thrice on
alternate days with pCD.III or pCD (n   8 per group). A week after the last
injection, spleens were harvested and single cell suspensions were cultured
with IL-2 and 10  g/ml each of the three MHC class I–binding epitopes
shown in Fig. 1C (cells from pCD.III-injected mice) or with IL-2 alone
(cells from pCD-injected mice). After 3 to 7 d in culture, cells were washed,
purified as live cells using Ficoll-Hypaque, and then enriched for T cells using MACS. The purified T cells (5   106 or 5   103) were injected intrave-
nously twice at 3-d intervals into 22-wk-old BWF1 mice (n   6 mice per group). 5 d after the second transfer, recipient animals were killed and their
spleen cells were tested for IgG anti-DNA Ab forming cells in an ELISPOT assay. Results are shown as the mean   SD IgG anti-DNA Ab forming cells
per 106 spleen cells. *P   0.02, recipients of T cells from pCD.III-vaccinated mice ( ) versus recipients of T cells from pCD-injected mice ( ).737 Fan et al.
compared with normal B cells (35). Such somatic muta-
tions in the autoantibody VH regions may create unique T
cell epitopes that would commonly target autoantibody-
specific B cells. Consistent with this explanation, the VH
peptide-reactive CTLs kill dsDNA-specific B cells that ex-
press the VH epitope but do not kill nonautoreactive B cells
that do not express the relevant epitopes (Fig. 3 A).
In a GenBank database analysis, 17% of Igs that express
three anti-DNA VH–derived T cell epitope sequences are
nonself-reactive Ig (11, and unpublished data). The lysis of
B cells that express the nonself-reactive Ig containing such
T cell epitope sequences would be a tolerable clinical side
effect. In our experiments, however, anti-VH CTLs did not
kill B cells from nonautoimmune CWF1 (Fig. 2 B, left
panel), young, preautoimmune female BWF1 (Fig. 3 B, left
panel), or young male BWF1 mice (unpublished data) that
did not have detectable autoantibodies in their circulation.
B cells from these mice, however, became the target of
anti-VH CTLs, when they were pulsed with the appropri-
ate VH–derived peptide (Fig. 2 B, middle panel, and un-
published data). Thus, nonautoreactive B cells can also be-
come the target of anti-VH CTLs, if they express an Ig that
contains the epitope and can process and display the pep-
tide–MHC class I complexes, or if the peptide is loaded on
to their MHC class I exogenously. The latter scenario can
be imagined in mice or humans with SLE who have large
amounts of circulating autoantibodies that might undergo
physiologic proteolysis, releasing VH peptides into the
plasma, which could then bind MHC class I on normal B
cells. This would result in VH-specific killing of both au-
Figure 5. Effect of VH mini-
gene vaccination on lupus ne-
phritis and survival. 3-mo-old
BWF1 mice were vaccinated with
pCD.III ( ), pCD ( ), or PBS
( ), as described in Fig. 4 (n  
14 mice per group pooled from
two experiments). The percent
cumulative incidence of severe
( 300 mg/dl) proteinuria and
survival are shown in A and B,
respectively. P   0.01 to   0.001
by log rank test in pCD.III-
vaccinated versus pCD- or
PBS-injected mice; P   NS in
pCD versus PBS groups. (C)
Representative H E– or PAS-
stained renal sections from BWF1
mice inoculated with PBS (left
panels) or pCD.III (right panels).
Kidneys were harvested at the age
of 40 wk, or before in mice that
had terminal disease. Findings
were similar in the two control
groups (PBS and pCD) of mice,
which had severe glomerular
sclerosis (GSc), interstitial infil-
trates (INF), fibrous and cellular
crescents (CRE), and tubular
atrophy (TA). In contrast, the
pCD.III-vaccinated mice had
only mild glomerular (GP) or
mesangial proliferation (MP).
Original magnification:  200 in
the top panels and  400 in
bottom panels.738 Anti-VH Cytotoxic T Lymphocytes Ablate Autoreactive B Cells in Lupus
toreactive and normal B cells. This scenario, however, is
not supported by our data, as only  20% of splenic B cells
from BWF1 mice with advanced disease were killed by
anti-VH CTLs (Fig. 3 B, right panel). In vivo, the anti-VH
CTLs must have specifically targeted anti-DNA Ab-express-
ing B cells, as serum anti-DNA Ab levels, but not the total
serum IgG, were significantly decreased in minigene-vacci-
nated BWF1 mice (Fig. 4 B).
Inclusion of MHC class II–binding epitopes in minigene
constructs allowed us to track the expression of minigenes in
vivo by determining serum levels of peptide-specific Abs (Fig.
2 A). The MHC class II–binding epitopes may also activate
peptide-specific CD4  Th cells, which are known to pro-
mote CD8  CTL priming (27), thus improving the efficacy
of the vaccination. Additionally, very high levels of expression
of MHC class II–binding VH epitopes may induce a high-
zone tolerance in CD4  Th cells (36), which may also im-
prove the efficacy of vaccination. This may be possible, as in-
travenous administration of large doses of soluble MHC class
II–binding VH peptides is known to induce tolerance in
CD4  Th cells and inhibit disease in BWF1 mice (36). In
contrast, repeated immunizations by subcutaneous injections
of MHC class II–binding VH peptides in adjuvant activates
CD4  Th cells that accelerate disease in BWF1 mice (9).
Thus, inclusion of MHC class II–binding epitopes in mini-
gene constructs may also potentially worsen the efficacy of
vaccination, especially in older BWF1 mice that exhibit
stronger Th (antipeptide Ab) and weaker CTL responses than
in younger, prenephritic animals (unpublished data). Indeed,
although treatment of 24-wk-old BWF1 mice with pCD.III
decreased anti-DNA Ab levels and proteinuria (P   0.05–
0.06 versus pCD- or PBS-treated control mice; n   12 mice
per group; unpublished data), it was far less effective than
when the vaccination was initiated at a prediseased stage (Figs.
4 and 5). To address the possibility that decreased efficacy of
minigene treatment is due to inclusion of overlapping MHC
class II–binding Th epitopes in the construct, we generated
another plasmid DNA vector that encodes ‘pure’ MHC class
I–binding epitopes (underlined 8–9-mer sequences in Fig. 1
C). Treatment of 24-wk-old BWF1 mice that already had
clinical nephritis (proteinuria  100 mg/dl) with this vector
significantly decreased serum IgG anti-DNA Ab levels (P  
0.05, Student’s t test) and proteinuria (P   0.01, log rank test)
compared with the control PBS and pCD injected mice (n  
15 mice per group). By 36 wk of age, only 20% mice in the
minigene-treated group compared with 67 and 74% in the
PBS and pCD groups, respectively, had developed persistent,
severe proteinuria ( 300 mg/dl). Thus, in mice with full-
blown lupus, treatment with a minigene encoding CTL
epitopes alone is likely to be more effective than a minigene
that encodes both CTL and Th epitopes.
The beneficial effect of minigene treatment in 24-wk-
old BWF1 mice was associated with a significant decrease
in anti-DNA Ab-producing B cells. The mean   SE IgG
anti-DNA Ab-producing B cells were 308   48, 353  
70, and 158   28 per 106 spleen cells in 36-wk-old PBS,
pCD, and minigene-treated animals, respectively (P   0.05
in treated versus control mice, n   6 mice per group). To-
tal CD19  B and CD4  T cell numbers and relative per-
centages were also slightly lower (P   0.05–0.06), whereas
CD8  T cells were significantly higher (P   0.01) in mini-
gene-treated than in control mice. Minigene treatment did
not result in nonspecific inhibition of all Ig production, as
IgG anti–hen egg lysozyme Ab-producing B cell numbers
were similar in the treated and control mice immunized
with hen egg lysozyme (unpublished data).
The IdGN2 is an idiotype that is highly enriched in glo-
merular Ig deposits in kidneys from nephritic BWF1 mice
(37) and among nephritogenic anti-DNA Ab-producing B
cells, including A6.1 mAb, derived from diseased BWF1
mice (4, 38). We have recently found that an anti-IdGN2
Ab that was established by immunizing BWF1 mice with
A6.1 selectively binds to 8-mer sequences represented in
the VH1 and VH2 peptides (unpublished data). Thus,
IdGN2-expressing Ig may represent a subset of nephrito-
genic autoantibodies; B cells expressing such Ig may be
specifically targeted by CTLs reactive against VH1 and
VH2 epitopes. Indeed, IdGN2-positive ELISPOTs were
dramatically decreased in minigene-treated mice (28  
20) as compared with the control mice (PBS, 198   31;
pCD, 182   22 per 106 spleen cells, mean   SE; P  
0.001, n   6 mice per group). This suggests that VH mini-
gene treatment preferentially targets B cells that secrete
nephritogenic Abs.
Figure 6. Cytokine production by spleen cells is altered in minigene-
vaccinated mice. 10 d after the third injection of pCD.III, pCD, or PBS,
spleen cells from BWF1 mice were cultured without (Medium) or with
three VH peptides (VH1, VH2, and VH3, Peptide) for 48 h, and super-
natants were tested for IFN- , active TGF- , IL-4, and IL-13. Results
are expressed as the mean   SD pg/ml in five mice per group from one of
three similar experiments. *P   0.05; **P   0.01 in pCD-III-vaccinated
versus pCD- or PBS-injected groups (Student’s t test).739 Fan et al.
Overwhelming evidence supports a nephritogenic role
of anti-DNA Ab (3, 4). Several recent reports, however,
suggest that ‘circulating’ autoantibodies may not be essen-
tial for the development of lupus nephritis. For example,
MRL-lpr/lpr mice rendered deficient in circulating Ig de-
velop nephritis, although the disease in mutant mice is less
marked than in the intact mice (39). Another report
showed that treatment of nephritic BWF1 mice with
CTLA4Ig and anti-CD40 ligand Ab decreases proteinuria,
but does not decrease circulating anti-DNA Ab levels; anti-
DNA Ab-producing splenic B cells, however, are reduced
in the treated mice (40). Genome-wide studies in lupus-
prone mice also suggest a dissociation of some anti-DNA
Ab loci from glomerulonephritis or mortality loci (41–43),
while other loci such as MHC are linked to all three traits
(41). As nephritogenic anti-DNA Abs (4), which may be
regulated by MHC, may comprise only a fraction of circu-
lating anti-DNA Abs, it is not surprising that serum anti-
DNA Ab levels do not always correlate with the presence
of nephritis. Moreover, the deposition of anti-DNA Abs
may represent only one step in the development of lupus
nephritis; subsequent tissue damage may be caused by other
mechanisms. Irrespective of the role of circulating anti-
DNA Ab, functional B cells expressing surface Ig are essen-
tial for the development of lupus nephritis (39). Thus, our
data showing a profound effect of depletion of anti-DNA B
cells on the overall disease (Figs. 4 and 5) are consistent
with the published literature.
The CD8  CTL and suppressor responses are known to
be defective in patients with SLE (44, 45). A similar im-
pairment was observed in lupus-prone BWF1 mice when
they were immunized with synthetic peptides in CFA (un-
published data). The impairment in CD8  T cell responses
in BWF1 mice, however, could be overcome by adminis-
tration of peptides via a plasmid DNA vector (Fig. 3). This
effect of DNA vaccination is due primarily to the increased
access of peptides that are synthesized within cells to the
MHC class I antigen presentation pathway (28). In addi-
tion, cytokines produced during an immune response can
influence the generation of CTLs (32–34): in vivo CD8 
CTL activity is enhanced by IFN- , and diminished by
IL-4. In our experiments, vaccination with the VH peptide
minigenes, pCD.VH1 or pCD.III increased the production
of IFN-  and TGF-  and decreased IL-4 and IL-13 pro-
duction by spleen cells in a peptide-specific manner (Fig.
6). Thus, increased IFN-  and decreased IL-4 production
by minigene vaccination may further facilitate the induc-
tion of CTLs and enable mice and humans with lupus to
overcome the impairment in CTL responses. Additionally,
TGF-  selectively activates CD8  T cells to proliferate
(46) and can condition these cells to become suppressors of
Ab production (47). Thus, an increase in TGF-  may aug-
ment the priming of CTLs and enhance their capability to
inhibit autoreactive B cell Ig production in lupus mice.
Finally, we asked how would a therapeutic approach that
depends on restricted MHC types be applicable to the clin-
ical situation? Interestingly, screening of published anti-
DNA Ab sequences in BWF1 and MRL-lpr/lpr mice re-
veals that similar T cell epitope sequences are present in the
VH of anti-DNA Abs from genetically unrelated mouse
strains with SLE (11). Furthermore, such epitopes can bind
MHC class I molecules from many different mouse strains.
For example, peptide VH2 (Fig. 1 C) contains epitopes that
are predicted to bind MHC class I molecules in NZB (H2-
Kd), MRL-lpr/lpr (H2-Kk), and BXSB strains (H2-Kb and
H2-Db), and in humans (HLA-A*0201). Vaccination using
such promiscuous and shared epitopes may elicit anti-VH
CTLs across the MHC barrier. An alternative therapeutic
approach is to vaccinate using longer sequences of VH
genes, which may obviate the limitation of MHC type-
dependence. The longer VH sequences, however, may con-
tain both Th and CTL epitopes. A preferential processing
and presentation of Th epitopes might activate autoanti-
body-promoting Th cells and exacerbate lupus, thus reduc-
ing the beneficial effect of CTL epitopes. Indeed, our pre-
liminary results suggest that vaccination using a minigene
that encodes a ‘pure’ MHC class II-binding epitope with-
out any overlapping or adjacent MHC class I–binding
epitope exacerbates lupus nephritis (unpublished data).
In conclusion, altering the presentation of anti-DNA
VH-derived T cell epitopes by administering them as mini-
genes activates CD8  CTLs that ablate autoreactive B cells
in lupus-prone mice. This approach of inhibiting autoanti-
body production may pave the way for peptide-specific
treatments for patients with SLE (36, 48–55). In prelimi-
nary analyses, we have found strong HLA class I–binding
epitopes in the published VH gene sequences of human
anti-DNA mAbs (unpublished data). In these human anti-
DNA VH sequences, we will identify the CTL epitopes that
would be shared among lupus-related autoantibodies from
different patients, but would be rare in the normal human
Ig repertoire. A library of such epitopes would be helpful in
generating the designer minigene vaccines for patients with
SLE and other autoantibody-mediated diseases.
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